SMO and non-small cell lung carcinoma: Additionally, a significant reduction in cisplatinum chemoresistance in experimental in vitro models is achieved via inhibition of the SHH-SMO-GLI1 axis signaling with an SMO antagonist (GDC-0449) in both human NSCLC and SCLC cell lines [37].